Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor Elimusertib in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor Elimusertib in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Participants With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elimusertib (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bayer

Most Recent Events

  • 02 May 2023 Status changed from active, no longer recruiting to completed.
  • 30 Mar 2023 Planned End Date changed from 15 Mar 2024 to 11 Apr 2023.
  • 15 Feb 2023 Planned End Date changed from 16 Apr 2023 to 15 Mar 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top